## STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

Docket No. BOE0004US.NP

					l <b> </b>					
In Re	Application (	Of: Klokkers et al.								
Application No. 10/577,569		Filing Date 02/27/08	Examiner Sarah Alawadi	Customer No. 26259	Group Art Unit	Confirmation No. 6210				
Invent	ion: Pharm	naceutical Active-Ingi	edient-Containing Formulation	with Coating						
COMMISSIONER FOR PATENTS:										
This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.										
Check applicable statement herebelow:										
	Statement Under 37 CFR 1.97(e)(1)									
	Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the Information Disclosure Statement.									
Statement Under 37 CFR 1.97(e)(2)										
	□ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.									
******	Janana	Signature		Dated: Nov	ember 12, 2010					
Reg Lica 66 H Mai tel:	e Massey Lic istration No. ata & Tyrrell L. Main Stree Iton, New Je 856-810-1515 856-810-145	32,257 P.C. et ersey 08053 US	Certificate of Mailing by First Class Mail  I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on							
	_	c)licataandtyrrell.com		(Date	re of Person Mailing (	Correspondence				
cc:						•				

Typed or Printed Name of Person Mailing Correspondence

TRA	ANSMITTA	Docket No. BOE0004US.NP									
In Re Application Of: Klokkers et al.											
Application No.		Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.					
10/577,569		02/27/08	Sarah Alawadi	26259	1619	6210					
Title:	Pharmaceut	ical Active-Ingredien	t-Containing Formulation with C	Coating							
Address to:  Commissioner for Patents P.O. Box 1450  Alexandria, VA 22313-1450											
			37 CFR 1.97(b)								
1.	The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.										
			37 CFR 1.97(c)								
2.	CFR 1.97( Final Action	The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:									
	☑ the statement specified in 37 CFR 1.97(e);										
OR											
	☐ the f	ee set forth in 37 CF	R 1.17(p).								

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) BOE0004US.NP In Re Application of: Klokkers et al. Group Art Unit Confirmation No. Application No. Filing Date Customer No. Examiner 10/577,569 02/27/08 26259 Sarah Alawadi 1619 6210 Pharmaceutical Active-Ingredient-Containing Formulation with Coating Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Transmission by Facsimile\* Certificate of Mailing by First Class Mail I certify that this document and authorization to charge deposit I hereby certify that this correspondence is being deposited account is being facsimile transmitted to the United States with the United States Postal Service with sufficient postage Patent and Trademark Office (Fa as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on (Date) (Date) Signature Signature of Person Mailing Correspondence Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate \*This certificate may only be used if paying by deposit account. Janasy year Dated: November 12, 2010 Jane Massey Licata, Esq. Registration No. 32,257 Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053 US tel: 856-810-1515 fax: 856-810-1454 email: jmlicata@licataandtyrrell.com CC: